BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) entered into a non-binding letter of intent (“LOI”) with Ifowonco Informatics Incorporated as an initial step toward negotiating a definitive agreement that, if completed, would grant Onco an exclusive option relating to Ifowonco’s proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (“LAG-3”). The proposed collaboration is intended to combine Ifowonco’s oral small-molecule immune checkpoint technology with Onco-Innovations’ expertise in DNA damage response (“DDR”) therapeutics, translational oncology and clinical development, with the companies believing the combination of DDR inhibition and LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. Ifowonco’s program is…
